NanoSyrinx announces closure of its Pre-Seed investment round

The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S.

Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space.

NanoSyrinx is now preparing for its next full seed raise Q4-2020/Q1-2021, so if you’d like to be involved in the next round and join us on our journey, please get in touch!

Full press release details can be found here:

Follow us on social media to stay up to date!


Read more news

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more